BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

342 related articles for article (PubMed ID: 35297332)

  • 1. Tumor Microenvironment: Necroptosis Switches the Subtype of Liver Cancer While Necrosis Promotes Tumor Recurrence and Progression.
    Özdemir BH
    Exp Clin Transplant; 2023 Apr; 21(4):291-298. PubMed ID: 35297332
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oncogenic driver genes and tumor microenvironment determine the type of liver cancer.
    Wang G; Wang Q; Liang N; Xue H; Yang T; Chen X; Qiu Z; Zeng C; Sun T; Yuan W; Liu C; Chen Z; He X
    Cell Death Dis; 2020 May; 11(5):313. PubMed ID: 32366840
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Necroptosis microenvironment directs lineage commitment in liver cancer.
    Seehawer M; Heinzmann F; D'Artista L; Harbig J; Roux PF; Hoenicke L; Dang H; Klotz S; Robinson L; Doré G; Rozenblum N; Kang TW; Chawla R; Buch T; Vucur M; Roth M; Zuber J; Luedde T; Sipos B; Longerich T; Heikenwälder M; Wang XW; Bischof O; Zender L
    Nature; 2018 Oct; 562(7725):69-75. PubMed ID: 30209397
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Liver Cancer Cell of Origin, Molecular Class, and Effects on Patient Prognosis.
    Sia D; Villanueva A; Friedman SL; Llovet JM
    Gastroenterology; 2017 Mar; 152(4):745-761. PubMed ID: 28043904
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterization of the distinct immune microenvironments between hepatocellular carcinoma and intrahepatic cholangiocarcinoma.
    Jiang S; Lu H; Pan Y; Yang A; Aikemu A; Li H; Hao R; Huang Q; Qi X; Tao Z; Wu Y; Quan C; Zhou G; Lu Y
    Cancer Lett; 2024 Apr; 588():216799. PubMed ID: 38479553
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High mobility group A1 is expressed in metastatic adenocarcinoma to the liver and intrahepatic cholangiocarcinoma, but not in hepatocellular carcinoma: its potential use in the diagnosis of liver neoplasms.
    Abe N; Watanabe T; Izumisato Y; Suzuki Y; Masaki T; Mori T; Sugiyama M; Fusco A; Atomi Y
    J Gastroenterol; 2003; 38(12):1144-9. PubMed ID: 14714251
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Transthyretin promotes the invasion of combined hepatocellular cholangiocarcinoma by tumor-associated macrophages.
    Ke K; Lin J; Huang N; Yan L; Liao R; Yang W
    Cancer Rep (Hoboken); 2023 Oct; 6(10):e1888. PubMed ID: 37688511
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Look into hepatic progenitor cell associated trait: Histological heterogeneity of hepatitis B-related combined hepatocellular-cholangiocarcinoma.
    Cai X; Xiong J; Hu QG; Zhao QD; Wu D; Tang LG; Wan CD; Wei LX
    J Huazhong Univ Sci Technolog Med Sci; 2017 Dec; 37(6):873-879. PubMed ID: 29270746
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Insights into the role of STAT3 in intrahepatic cholangiocarcinoma (Review).
    Yang R; Song Y; Shakoor K; Yi W; Peng C; Liu S
    Mol Med Rep; 2022 May; 25(5):. PubMed ID: 35302174
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mutation inactivation of Nijmegen breakage syndrome gene (NBS1) in hepatocellular carcinoma and intrahepatic cholangiocarcinoma.
    Wang Y; Hong Y; Li M; Long J; Zhao YP; Zhang JX; Li Q; You H; Tong WM; Jia JD; Huang J
    PLoS One; 2013; 8(12):e82426. PubMed ID: 24349281
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Alternative lengthening of telomeres in primary hepatic neoplasms.
    Yasir S; Thompson S; Chen ZE; Knudson R; Knutson D; Kloft-Nelson S; Graham RP; Jain D; Simon SM; Wu TT; Torbenson M
    Hum Pathol; 2023 Jan; 131():79-86. PubMed ID: 36370823
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tumor Cell Biodiversity Drives Microenvironmental Reprogramming in Liver Cancer.
    Ma L; Hernandez MO; Zhao Y; Mehta M; Tran B; Kelly M; Rae Z; Hernandez JM; Davis JL; Martin SP; Kleiner DE; Hewitt SM; Ylaya K; Wood BJ; Greten TF; Wang XW
    Cancer Cell; 2019 Oct; 36(4):418-430.e6. PubMed ID: 31588021
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combined hepatocellular cholangiocarcinoma: Controversies to be addressed.
    Wang AQ; Zheng YC; Du J; Zhu CP; Huang HC; Wang SS; Wu LC; Wan XS; Zhang HH; Miao RY; Sang XT; Zhao HT
    World J Gastroenterol; 2016 May; 22(18):4459-65. PubMed ID: 27182157
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinicopathologic analysis of combined hepatocellular-cholangiocarcinoma according to the latest WHO classification.
    Akiba J; Nakashima O; Hattori S; Tanikawa K; Takenaka M; Nakayama M; Kondo R; Nomura Y; Koura K; Ueda K; Sanada S; Naito Y; Yamaguchi R; Yano H
    Am J Surg Pathol; 2013 Apr; 37(4):496-505. PubMed ID: 23388123
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MYC determines lineage commitment in KRAS-driven primary liver cancer development.
    D'Artista L; Moschopoulou AA; Barozzi I; Craig AJ; Seehawer M; Herrmann L; Minnich M; Kang TW; Rist E; Henning M; Klotz S; Heinzmann F; Harbig J; Sipos B; Longerich T; Eilers M; Dauch D; Zuber J; Wang XW; Zender L
    J Hepatol; 2023 Jul; 79(1):141-149. PubMed ID: 36906109
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chronic bile duct injury associated with fibrotic matrix microenvironment provokes cholangiocarcinoma in p53-deficient mice.
    Farazi PA; Zeisberg M; Glickman J; Zhang Y; Kalluri R; DePinho RA
    Cancer Res; 2006 Jul; 66(13):6622-7. PubMed ID: 16818635
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mixed hepatocellular cholangiocarcinoma tumors: Cholangiolocellular carcinoma is a distinct molecular entity.
    Moeini A; Sia D; Zhang Z; Camprecios G; Stueck A; Dong H; Montal R; Torrens L; Martinez-Quetglas I; Fiel MI; Hao K; Villanueva A; Thung SN; Schwartz ME; Llovet JM
    J Hepatol; 2017 May; 66(5):952-961. PubMed ID: 28126467
    [TBL] [Abstract][Full Text] [Related]  

  • 18.
    Hill MA; Alexander WB; Guo B; Kato Y; Patra K; O'Dell MR; McCall MN; Whitney-Miller CL; Bardeesy N; Hezel AF
    Cancer Res; 2018 Aug; 78(16):4445-4451. PubMed ID: 29871934
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mixed hepatocellular-cholangiocarcinoma may derive from "hepatogones".
    Hunt JP; Varnholt H
    Hepatobiliary Pancreat Dis Int; 2008 Feb; 7(1):105; author reply 105-6. PubMed ID: 18234649
    [No Abstract]   [Full Text] [Related]  

  • 20. A histopathological study on combined hepatocellular and cholangiocarcinoma: cholangiocarcinoma component is originated from hepatocellular carcinoma.
    Wakasa T; Wakasa K; Shutou T; Hai S; Kubo S; Hirohashi K; Umeshita K; Monden M
    Hepatogastroenterology; 2007 Mar; 54(74):508-13. PubMed ID: 17523309
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.